Cargando…

Tau Oligomers as Potential Targets for Alzheimer’s Diagnosis and Novel Drugs

A cumulative number of approaches have been carried out to elucidate the pathogenesis of Alzheimer’s disease (AD). Tangles formation has been identified as a major event involved in the neurodegenerative process, due to the conversion of either soluble peptides or oligomers into insoluble filaments....

Descripción completa

Detalles Bibliográficos
Autores principales:	Guzmán-Martinez, Leonardo, Farías, Gonzalo A., Maccioni, Ricardo Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808896/ https://www.ncbi.nlm.nih.gov/pubmed/24191153 http://dx.doi.org/10.3389/fneur.2013.00167

Ejemplares similares

Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches
por: Morales, Inelia, et al.
Publicado: (2014)

Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
por: Guerrero-Muñoz, Marcos J., et al.
Publicado: (2015)

Characteristics of Tau Oligomers
por: Ren, Yan, et al.
Publicado: (2013)

Hyperphosphorylation-Induced Tau Oligomers
por: Iqbal, Khalid, et al.
Publicado: (2013)

Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage
por: Shafiei, Scott S., et al.
Publicado: (2017)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration
por: Cortés, Nicole, et al.
Publicado: (2018)

Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies
por: Galzitskaya, Oxana V.
Publicado: (2020)

PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer’s Disease
por: Luna-Viramontes, Nabil Itzi, et al.
Publicado: (2020)

The prion-like transmission of tau oligomers via exosomes
por: Jackson, Noel A., et al.
Publicado: (2022)

“Tau Oligomers,” What We Know and What We Don’t Know
por: Sahara, Naruhiko, et al.
Publicado: (2014)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau
por: Lasagna-Reeves, Cristian A., et al.
Publicado: (2012)

The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer’s Disease (AD)
por: Mroczko, Barbara, et al.
Publicado: (2019)

The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease
por: Viola, Kirsten L., et al.
Publicado: (2022)

LTP and memory impairment caused by extracellular Aβ and Tau oligomers is APP-dependent
por: Puzzo, Daniela, et al.
Publicado: (2017)

Understanding the Pathophysiological Actions of Tau Oligomers: A Critical Review of Current Electrophysiological Approaches
por: Hill, Emily, et al.
Publicado: (2020)

Tau Oligomers Neurotoxicity
por: Niewiadomska, Grazyna, et al.
Publicado: (2021)

Alzheimer’s Disease and Tau Self-Assembly: In the Search of the Missing Link
por: González, Andrea, et al.
Publicado: (2022)

Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
por: Hillen, Heinz
Publicado: (2023)

Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies
por: Castillo-Carranza, Diana L, et al.
Publicado: (2017)

Alzheimer´s Disease in the Perspective of Neuroimmunology
por: Maccioni, Ricardo B., et al.
Publicado: (2018)

Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives
por: Lo Cascio, Filippa, et al.
Publicado: (2019)

Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer’s disease
por: Marcatti, Michela, et al.
Publicado: (2022)

Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimer’s disease
por: Puangmalai, Nicha, et al.
Publicado: (2022)

Novel Nutraceutical Compounds in Alzheimer Prevention
por: Maccioni, Ricardo Benjamin, et al.
Publicado: (2022)

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease
por: Ferreira, Sergio T., et al.
Publicado: (2015)

Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
por: Hector, Audrey, et al.
Publicado: (2021)

New Insights Into Drug Discovery Targeting Tau Protein
por: Soeda, Yoshiyuki, et al.
Publicado: (2020)

ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
por: Krafft, Grant A., et al.
Publicado: (2022)

Phospho-Tau and Cognitive Decline in Alzheimer's Disease. Commentary: Tau in physiology and pathology
por: DeFelipe, Javier
Publicado: (2016)

Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain
por: DeVos, Sarah L., et al.
Publicado: (2018)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
por: Marksteiner, Josef, et al.
Publicado: (2022)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

The Association of Tau With Mitochondrial Dysfunction in Alzheimer's Disease
por: Cheng, Ying, et al.
Publicado: (2018)

Alzheimer's Disease: Tau Pathology and Dysfunction of Endocytosis
por: Ando, Kunie, et al.
Publicado: (2021)

Implication of tau propagation on neurodegeneration in Alzheimer’s disease
por: Lamontagne-Kam, Daniel, et al.
Publicado: (2023)

Tau kinetics in Alzheimer's disease
por: Hier, Daniel B., et al.
Publicado: (2022)

Shilajit: A Natural Phytocomplex with Potential Procognitive Activity
por: Carrasco-Gallardo, Carlos, et al.
Publicado: (2012)

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
por: Gerson, Julia E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u8ghrkiih9csp4ipco3vms9dfb